Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Emcure Pharmaceuticals Ltd

₹ 1,4904.10%
05 Jan – close price
🔗emcure.co.in•BSE: 544210•NSE: EMCURE
Market Cap₹ 28,237 Cr.
Current Price₹ 1,490
High / Low₹ 1,525
Stock P/E65.2
Book Value₹ 170
Dividend Yield0.20 %
ROCE13.5 %
ROE11.6 %
Face Value₹ 10.0
Sales₹ 4,664 Cr.
OPM17.5 %
Mar Cap₹ 28,237 Cr.

ABOUT

Incorporated in 1981, Emcure PharmaceuticalsLtd manufactures and markets pharmaceutical products globally[1]

KEY POINTS

Business Overview:[1][2]EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsJv Partnerships AcquisitionsRevenue Guidance Vs ActualsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1728.9035.93414821.020.933124.952.5614478.318.9320.2154964.0130.1211543.963117.955.3312.970.07
2.Divi's Lab.6363.5067.98168930.930.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.9613.530.01
3.Torrent Pharma.3869.8060.45130971.620.83591.0032.493302.0014.3027.0512248.0032.602166.53600.1715.5013.260.33
4.Cipla1519.8022.56122765.070.861353.373.737589.447.6422.7228349.5725.405441.141351.173.7314.720.01
5.Dr Reddy's Labs1250.0018.07104328.800.641336.807.288828.309.8322.6934310.0024.645772.201347.102.9012.950.16
6.Lupin2083.7022.0195183.170.581484.8373.347047.5124.2321.3024750.6927.254324.631477.924.8512.410.32
7.Zydus Lifesci.921.9518.4592769.741.191238.6040.926123.2016.9224.3124493.9031.105029.351283.603.6714.640.38
8.Emcure Pharma1489.5065.2528236.830.20117.6235.321260.6014.1213.544664.1717.46432.74117.628.795.670.50
–Median: 151 Co.410.930.91678.70.1112.5711.71152.6410.5814.8574.0115.9343.8413.493.158.210.22

Quarterly Results

Standalone figures in ₹ crores

Dec 2023Dec 2024Jun 2024Jun 2025Mar 2024Mar 2025Sep 2023Sep 2024Sep 2025
Sales
8701,0299701,0979031,2788881,1051,261
Expenses
7469128558697961,0347889471,036
Operating Profit
124117115228106245100158225
Other Income
332733182522304923
Profit before tax
6167551663518636119158
Tax %
20%25%27%26%18%25%24%27%26%
Net Profit
485040123291402787118
EPS in Rs
2.672.652.236.481.607.371.514.606.20

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
2,4542,3763,1543,3873,1073,4984,3824,664
Expenses
1,8831,9482,4102,5932,6683,0563,7593,850
Operating Profit
570428743795439442623815
Other Income
56899413311912914290
Interest
12713712314516716611392
Depreciation
130155156166179205225235
Profit before tax
370225557616212200428577
Net Profit
284175420447160161317430
EPS in Rs
15.689.6923.2524.718.858.8816.7422.70
Dividend Payout %
16%26%4%12%23%23%18%–

Compounded Profit Growth

10 Years:%
5 Years:7%
3 Years:-14%
TTM:104%

Compounded Sales Growth

10 Years:%
5 Years:13%
3 Years:9%
TTM:21%

Return on Equity

10 Years:%
5 Years:15%
3 Years:10%
Last Year:12%

Stock Price CAGR

10 Years:%
5 Years:%
3 Years:%
1 Year:7%

Balance Sheet

Standalone figures in ₹ crores

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
181181181181181181189190
Reserves
1,5971,7342,1211,5321,6611,7542,8353,024
Borrowings
1,2241,2431,6651,5791,7731,5958571,612
Other Liabilities
5767138971,0321,0011,2261,5341,602
Total Liabilities
3,5783,8714,8634,3234,6164,7575,4166,428
Fixed Assets
1,1001,1661,2781,1511,4331,7181,7591,755
Gross Block
1,563.011,761.832,013.342,031.302,472.142,952.693,183.30–
Accumulated Depreciation
463.08595.77735.44879.821,039.441,234.451,424.24–
CWIP
40632619223925310699113
Investments
311408864563690684678979
Other Assets
1,7611,9712,5292,3692,2402,2482,8803,580
Total Assets
3,5783,8714,8634,3234,6164,7575,4166,428

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
371385775428505585558
Cash from Investing Activity
-276-169-836-394-271-173-438
Cash from Financing Activity
-53-4631-343-55-288-49
Net Cash Flow
42170-30-30918012471

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
13517511610912411599
Inventory Days
243200182202214206189
Days Payable
159197168166203220204
Cash Conversion Cycle
22017713014413510184
Working Capital Days
506019170-461
ROCE %
–13%20%21%11%10%14%

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
78.08%77.94%77.92%77.92%77.88%
FIIs
2.91%3.05%3.06%2.86%3.29%
DIIs
3.96%3.87%3.44%2.84%4.36%
Public
15.05%15.15%15.58%16.39%14.46%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Emcure Pharma Slashes Poviztra® Price by 55% to Boost Patient Access

2nd April 2026, 8:54 pm

Emcure's subsidiary acquires Canadian cosmetic firm Cutimed Inc. for up to CAD $5.05 million.

2nd April 2026, 3:10 am

Emcure Pharmaceuticals Closes Trading Window from April 1, 2026

30th March 2026, 11:34 pm

Emcure Seeks Shareholder Approval for Independent Director Appointment

25th March 2026, 1:15 am

Emcure Pharma Shareholders Approve Re-appointment of Three Independent Directors

24th March 2026, 7:43 pm

Published by Other Websites

External media mentions & references

Emcure Slashes Obesity Drug Price 55%; Abbott, Generics Spark Pharma Price War

2nd April 2026, 10:10 pm

Emcure Pharma Slashes Weight Drug Price 55% to Boost Patient Access

2nd April 2026, 9:53 pm

Emcure Pharma Slashes Semaglutide Price 47% to Boost Patient Access

2nd April 2026, 8:13 pm

Emcure Slashes Obesity Drug Price 55% Amid Fierce Generic Competition

2nd April 2026, 8:08 pm

India's GLP-1 Market War: Patent Expiry Sparks Price Battle

31st March 2026, 5:51 am

News Articles

Editorial & research coverage

Indian Earnings Mixed Amid Global Tech Jitters; NSDL Lock-in Expiry Looms
Indian Earnings Mixed Amid Global Tech Jitters; NSDL Lock-in Expiry Looms

5th February 2026, 7:44 am

Emcure Pharma Lock-In Expiry: 20% Equity to Hit Market
Emcure Pharma Lock-In Expiry: 20% Equity to Hit Market

12th January 2026, 7:46 am

Emcure Pharma Hits 52-Week High on Weight-Loss Drug; Analyst Sees Further Gains
Emcure Pharma Hits 52-Week High on Weight-Loss Drug; Analyst Sees Further Gains

7th January 2026, 4:41 pm

Experts Identify 8 Stocks for January 7 Trading Gains
Experts Identify 8 Stocks for January 7 Trading Gains

7th January 2026, 7:21 am

Emcure Pharma's Gujarat Plant Gets US FDA 'Clean Chit': Major Boost for Exports?
Emcure Pharma's Gujarat Plant Gets US FDA 'Clean Chit': Major Boost for Exports?

23rd December 2025, 8:22 pm

Documents

Announcements

Closure of Trading Window

25 Dec - Trading window closed from Jan 1, 2026 until 48 hours after unaudited results for quarter ending Dec 31, 2025.

Update On US FDA Inspection At Our Manufacturing Facility Located At Kadu, Surendranagar, Gujarat, India.

23 Dec - US FDA issued EIR: Kadu Surendranagar facility classified 'No Action Indicated' on Dec 23, 2025.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

22 Dec - Emcure launches Poviztra semaglutide pens in India; five strengths; price from ₹8,790/month; exclusive distributor.

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

16 Dec - Allotment of Equity Shares pursuant to exercise of ESOPs under the Emcure- Employee Stock Option Scheme 2013

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

1 Dec 2025 - Virtual group investor meeting with BOB Caps on Dec 3, 2025.

Annual Reports

Financial Year 2025

(from bse)

Credit Ratings

Rating update

5 Dec 2025 from crisil

Rating update

17 Oct 2025 from crisil

Rating update

7 Oct 2025 from care

Rating update

6 Nov 2024 from crisil

Rating update

12 Aug 2024 from care

Rating update

19 Jul 2024 from crisil

Concalls

Nov 2025

TranscriptPPTRecording

Aug 2025

TranscriptRecording

May 2025

Transcript

Feb 2025

TranscriptRecording

Nov 2024

Transcript

Aug 2024

Transcript

Stock Analysis

Description

Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally.

Key Growth Triggers

Currently no data available for Key Growth Triggers.

Order Book

Currently no data available for Order Book.

Key Red Flags

Currently no data available for Key Red Flags.

Key Dates To Watch

  1. Quarter ended December 31, 2025: The period for which the RTA confirmation certificate was issued.

Corporate Announcements

2nd Apr 26
Impact Rating: 7
Emcure Pharmaceuticals is reducing the price of its obesity drug Poviztra® (semaglutide injection) by up to 55% for the starting dose and an average of 47% across all doses, effective April 3, 2026.
1st Apr 26
Impact Rating: 8
Emcure's subsidiary acquired Canadian cosmetic firm Cutimed Inc. for up to CAD $5.05 million cash. Cutimed, with CAD $2.8 million turnover, will be amalgamated with Emcure's subsidiary, Mantra Pharma Inc.
30th Mar 26
Impact Rating: 5
Emcure Pharmaceuticals will observe a trading window closure for its designated persons starting April 1, 2026. The window will reopen 48 hours after the company declares its audited financial results for the quarter and fiscal year ending March 31, 2026.
24th Mar 26
Impact Rating: 6
Emcure Pharmaceuticals is seeking shareholder approval through a postal ballot for the appointment of Mr. C S Muralidharan as an Independent Director for a three-year term commencing April 1, 2026.
24th Mar 26
Impact Rating: 7
Shareholders of Emcure Pharmaceuticals have approved the continuation of three Independent Directors through a postal ballot, with their new terms commencing in April and June 2026.